Previous 10 | Next 10 |
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of MEI Pharma, Inc. (Nasdaq: MEIP) concerning the Company and its directors’ and officers’ possible violations of state laws. If you own MEI Pharma stock, would like to learn more about these claim...
– Safety Profile Observed to Date as Monotherapy and in Combination with Venetoclax Suggests no Overlapping Toxicity – – Initial Results from Correlative Studies Demonstrate On-target Reductions in Mcl-1 and RNA Pol II p-S2 – MEI Pharma, Inc. (Nasdaq:...
2023-11-09 17:42:54 ET More on MEI Pharma Seeking Alpha’s Quant Rating on MEI Pharma Historical earnings data for MEI Pharma For further details see: MEI Pharma GAAP EPS of $8.46, revenue of $65.3M
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the quarter ended September 30, 2023 and highlighted recent corporate events. ...
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced it will participate in the Stifel 2023 Healthcare Conference. David Urso, president and chief executive officer, will present a company overview and business upd...
2023-11-06 17:02:43 ET More on MEI Pharma MEI Pharma, Inc. (MEIP) Q4 2023 Earnings Call Transcript MEI Pharma GAAP EPS of -$4.78 beats by $0.92, revenue of $48.82M beats by $0.53M MEI Pharma FY 2023 Earnings Preview Seeking Alpha’s Quant Rating on MEI ...
MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that pursuant to the previously disclosed cooperation agreement with Anson Funds and Cable Car Capital, the Company’s Board ...
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that an abstract highlighting clinical data from the monotherapy dose escalation stage of the ongoing Phase 1 study evaluating voruciclib, a selective oral cycli...
Commits to Capital Return of Up to $3.15 per Share Adds Three New Directors and Forms Capital Allocation Committee of the Board MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) and Anson Funds and Cable Car Capital (“Anson and Cable Car”) today announc...
Files Definitive Consent Revocation Statement Mails Letter to Stockholders Highlighting the Path to Realizing the Full Value of Their MEI Investment Urges Stockholders Not to be Misled by Anson Advisors and Cable Car Capital and Not to Consent to Their Agenda MEI Pharma,...
News, Short Squeeze, Breakout and More Instantly...
– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway – MEI Pharma, Inc. ...
– Cohort 1 Exceeds Predetermined Non-Progression Threshold in the Ongoing Phase 1b Study – – ME-344 in Combination with Bevacizumab was Generally Well-tolerated with no Evidence of Overlapping Toxicity – – MEI to Continue Advancing ME-344 via Dev...
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a firesi...